Study Shows Digestive Drug Amitiza Provides Long-Term Relief
Posted on: Tuesday, 24 October 2006, 12:01 CDT
Takeda and Sucampo Pharmaceuticals have said that their constipation drug Amitiza showed long-term relief of symptoms of in a recent study.
In the study 60% of patients treated with Amitiza experienced a spontaneous bowel movement within 24 hours of treatment, and 80% experienced a spontaneous bowel movement within 48 hours of treatment.
Additionally, Amitiza, the first selective chloride channel activator approved by the FDA for the treatment of chronic idiopathic constipation, showed improvement in long-term symptom relief of this disorder with significant improvements in constipation severity, abdominal bloating and discomfort for up to 12 months.
"These results are encouraging for physicians who treat patients with constipation because there are few treatments approved for chronic constipation that can be used long term," said Satish Rao, professor of medicine and director, Neurogastroenterology and GI Motility at University of Iowa.
Constipation, one of the most common digestive complaints, accounts for more than 2.5 million doctor visits in the US each year according to the ACG.
Source: Datamonitor
Related Articles
- Johns Hopkins and AANP Lead Evidence-Based Performance Improvement Initiative to Deliver Tangible Benefits in Constipation Treatment & Outcomes
- New AMITIZA 8 Mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women With Irritable Bowel Syndrome With Constipation (IBS-C)
- ''Move to AMITIZA'' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
- FDA Accepts Sucampo's sNDA for Lubiprostone (8 Mcg) for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C)
- Sucampo Pharmaceuticals Submits Supplemental New Drug Application for Lubiprostone to Treat Irritable Bowel Syndrome With Constipation
- Study Demonstrated AMITIZA(TM) (Lubiprostone) Showed Efficacy Within 24 and 48 Hours of Treatment
- AMITIZA(TM) (Lubiprostone) Phase III Constipation Trial Results Demonstrate Improvements in Symptoms of Irritable Bowel Syndrome With Constipation
- AMITIZA(TM) (Lubiprostone), the First Selective Chloride Channel Activator for the Treatment of Chronic Idiopathic Constipation, Launches in the United States
- Sucampo Obtains FDA Approval for AMITIZA(TM) Capsules As Treatment for Chronic Idiopathic Constipation in Adults
 |
 |
User Comments (0)
RSS Feeds